這是一項隨機、開放標籤、多中心、全球性第三期研究，旨在確定 durvalumab + tremelimumab 聯合治療對比鉑類標準治療化療，用於表皮生長因子受體（EGFR）及間變性淋巴瘤激酶（ALK）野生型晚期或轉移性 NSCLC 患者第一線治療的療效與安全性。

適應症：Non Small Cell Lung Carcinoma NSCLC

收案條件

For inclusion in the study, patients should fulfill the following criteria:
Aged at least 18 years
Documented evidence of Stage IV NSCLC
No activating EGFR mutation or ALK rearrangement
No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC
World Health Organization (WHO) Performance Status of 0 or 1
No Prior exposure to Immune Mediated Therapy (IMT), including, but not limited to, other antiCTLA4, antiPD1, anti PDL1,or antiPDL2 antibodies, excluding therapeutic anticancer vaccines

Mixed small cell lung cancer and NSCLC histology, sarcomatoid variant
Brain metastases or spinal cord compression unless the patient is stable (asymptomatic; no evidence of new or emerging brain metastases) and off steroids for at least 14 days prior to start of study treatment.
Active or prior documented autoimmune or inflammatory disorders (e.g., Crohn's disease, ulcerative colitis)

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

Durvalumab 聯合 Tremelimumab 對比標準治療作為轉移性非小細胞肺癌（NSCLC）第一線治療的研究（NEPTUNE）